Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $446.4 million specializing in mRNA therapeutics and vaccines, stands at a ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

Sen. Brandon Shippy, R-New Plymouth, is proposing to put a 10-year pause certain types of vaccines that were used for some of ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking system and its counterpart on the station.

A new class of lipids developed by Penn Engineers improve the rates at which lipid nanoparticles (LNPs) successfully deliver ...

The measure would seem a premptive strike at a growing industry. No food engineered to include vaccines are approved for use ...

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Lehigh Valley’s health networks are seeing abnormally high cases of the stomach bug that’s taking a large number of people ...

Polk County’s level of immunization for kindergartners dropped from 96.3% in 2021 to 93.2% in 2023, still above the statewide ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.